Topics

Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria.

07:03 LMT 1st January 0000 | BioPortfolio

Summary of "Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: Journal of cutaneous medicine and surgery
ISSN: 1615-7109
Pages: 201-202

Links

DeepDyve research library

PubMed Articles [9948 Associated PubMed Articles listed on BioPortfolio]

Ligelizumab for Chronic Spontaneous Urticaria.

In the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control. Ligelizumab is a next-generation high-affinity humanized m...

Omalizumab response correlates with reduced IFN-γ-, IL-10- and IL-31-secreting cells in chronic spontaneous urticaria.

The anti-IgE antibody omalizumab has been approved for the treatment of chronic spontaneous urticaria (CSU) in patients insufficiently responding to antihistamines. However, its mode of action in CSU ...

Response of FcεRI-bearing leukocytes to omalizumab in chronic spontaneous urticaria.

The pathogenesis of chronic spontaneous urticaria (CSU) and the mechanism of action of omalizumab in CSU remains unclear.

Ligelizumab for Chronic Spontaneous Urticaria.

Ligelizumab for Chronic Spontaneous Urticaria.

Clinical Trials [8998 Associated Clinical Trials listed on BioPortfolio]

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

The purpose of this extension study is to establish efficacy and safety of ligelizumab. This will be assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who have ...

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

This clinical study is designed to evaluate the pharmacokinetics, safety and efficacy of ligelizumab in children from 12 to

OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients

This trial will assess the efficacy of optimized re-treatment therapy with omalizumab (150mg or 300mg) after relapse, in patients with Chronic Spontaneous Urticaria who were clinically wel...

Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria

The purpose of this study is to demonstrate the efficacy and safety of omalizumab, compared with placebo, as an add-on to H1AH therapy in adult patients suffering from CSU who remain sympt...

A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

The purpose of this study is to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remain symptomatic despite standard of care treatment by demonstr...

Medical and Biotech [MESH] Definitions

A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.

A long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria. The drug is well tolerated and has no anticholinergic side effects.

An extremely rare condition manifested as monoclonal IMMUNOGLOBULIN M dysproteinemia without features of lymphoproliferative disease, but with chronic urticaria, fever of unknown origin, disabling bone pain, hyperostosis, and increased erythrocyte sedimentation rate.

A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.

A spontaneous diminution or abatement of a disease over time, without formal treatment.

Quick Search


DeepDyve research library

Searches Linking to this Article